Lucemyra FDA Approval History
FDA Approved: Yes (First approved May 16, 2018)
Brand name: Lucemyra
Generic name: lofexidine hydrochloride
Dosage form: Tablets
Company: US WorldMeds
Treatment for: Opiate Withdrawal
Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.
Development timeline for Lucemyra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.